SAN DIEGO, Oct. 6, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. will be presenting at the 13th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.
Trovagene is scheduled to present at the 13th Annual BIO Investor Forum at the Palace Hotel in San Francisco, CA on October 8, 2014 at 3:00 p.m. Mr. Schuh will be available for one-on-one meetings during the conference. The presentation will be webcast live at http://www.veracast.com/webcasts/bio/investorforum2014/44212111772.cfm and can also be accessed through the investor relations page at www.trovagene.com. A replay of the presentation will be available at www.trovagene.com and will be archived for 90 days.
About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.
Contact | ||
Investor Relations | Media Relations | |
David Moskowitz and Amy Caterina Investor Relations | Ian Stone Account Director | |
Trovagene, Inc. | Canale Communications, Inc. | |
858-952-7593 | 619-849-5388 | |
Logo - http://photos.prnewswire.com/prnh/20120620/LA28014LOGO
SOURCE Trovagene, Inc.
